ABSTRACT OBJECTIVE: This study investigated the effects of chronic melatonin treatment on gene expression of α 1 -, α 2 -, β 1 -and β 2 -adrenoceptors in the hippocampus of rats subjected to chronic unpredictable mild stress (CUMS). BACKGROUND: Preclinical studies have also shown that melatonin prevented short-and long-term memory impairments and exhibited antidepressant-like actions. METHODS: For this study, we used 24 animals, which were divided into four groups, and the experiment lasted 4 weeks. We quantifi ed the changes in mRNA and protein levels of α 1 -, α 2 -, β 1 -and β 2 -adrenoceptors in the hippocampus after melatonin treatment. RESULTS: Our results demonstrated a decreased gene expression of α 1 -, α 2 -and β 2 -adrenoceptors in the hippocampus of rats subjected to unpredictable chronic mild stress, while there was no change in gene expression of β 1 -adrenoceptors. Melatonin treatment in the CUMS rats prevented the stress-induced decrease in mRNA and protein levels of α 1 -and β 2 -adrenoceptors, whereas did not affect either on mRNA or protein level of β 1 -and α 2 -adrenoceptors. CONCLUSION: Our data suggest that melatonin, by increasing reduced levels of α 1 -and β 2 -adrenoceptors mRNA and protein in the hippocampus of chronic stressed rats, may be benefi cial in conditions such as chronic stress and provides an experimental opportunity to probe into further molecular mechanisms underlying the regulation of these receptor subtype (Fig. 2, Ref. 28 ). Text in PDF www.elis.sk.
Introduction
Melatonin is a neurohormone primarily synthesized by the pineal gland during darkness (1) with a well-established role in regulating seasonal and circadian rhythms. Renewed attention has been given to the role of melatonin in modulating behavior, immune system, and responses to stress, cancer and aging (2) . Also, it has been proved that melatonin had anti-infl ammatory and antioxidant action (3) . Preclinical studies have also shown that melatonin prevented short-and long-term memory impairments induced by chronic sleep deprivation and exhibited antidepressant-like actions (4, 5) . Of the many brain regions affected in depression, the hippocampus is well known for its role in cognition stress sensitivity to emotional and memory impairments (6, 7) . Hippocampus is sensitive to stress, which activates noradrenaline terminals deriving from the locus coeruleus (8) . Activation of the noradrenergic system may play an important integrative function in coping with and adapting to stress. Adrenergic receptors (α-and β-subtypes) are the basic targets of noradrenaline, especially in mediating sympathetic activation in central nervous system. It has been proposed that these receptors trigger similar changes in the CNS during a successful adaptation to chronic stress and antidepressant therapy to yield adaptive changes in neural output or plasticity (6) .
There are reports concerning the changes in the density of adrenoceptors in depressed individuals. Postmortem studies on brains of suicide victims indicated an increase in cortical α 1 -and α 2 -adrenoceptors (9, 10). β-adrenoceptors have also been implicated in the pathophysiology of depression. Several studies support the thesis that the activation of β 1 -and β 2 -adrenoceptors in the CNS leads to antidepressant-like effect (11, 12) . De Paermentier and co-workers (13) showed a decreased density of cortical β-adrenoceptors in the antidepressant-free depressed suicide victims. There is no information regarding the direct action of melatonin on the expression of α-and β-adrenergic receptors in hippocampus of chronically stressed rats. CUMS is currently regarded by many investigators as one of the most naturalistic and predictive animal models of depression.
In this context, we investigated the effects of chronic melatonin treatment on gene expression of α 1 -, α 2 -, β 1 -and β 2 -adrenergic receptors in the hippocampus of rats subjected to CUMS.
Methods
The experiment was performed on male Wistar rats (11 weeks old, 250-310 g). The care was taken to minimize the pain and discomfort of the animals according to the guidelines of the Ethical Committee for the use of laboratory animals of the "Vinca" Institute based on EU directive 2010/63EU.
For this study, we used 24 animals, which were divided into four groups. First group was control (unstressed). animals received injection of vehicle daily (0.9 % NaCl containing 5 % ethanol). Second group was control (unstressed) and animals received melatonin. Third group was chronic unpredictable mildly stressed group. The animals from this group also received vehicle. In the fourth group were chronic unpredictable mildly stressed animals, also receiving melatonin. Melatonin was given in dose of 10 mg/kg body weight by intraperitoneal (i.p.) route, between 2:00 and 3:00 p.m.
The chronic unpredictable mild stress (CUMS) procedure was a variation of methods described by Grippo et al (14) . The day after the CUMS procedure, all animals were sacrifi ced by decapitation, hippocampus was quickly removed on ice, frozen in liquid nitrogen and stored at -70 °C until it was analyzed.
Total RNAs from hippocampal tissue was extracted using TRIzol ® Reagent (Thermo Fischer Scientifi c, MA USA) according to the manufacturer's instructions. Reverse transcription was performed using Ready-To-Go You-Prime First-Strand Bead (GE 
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Healthcare Life Sciences, PA USA) and pd (N) 6 primer according to manufacturer's protocol. Real-Time RT-PCR assay was done exactly as previously described by Gavrilovic et al (15) . TaqMan PCR reaction was carried out using Assay-on-Demand Gene Expression Products (Thermo Fischer Scientifi c, MA USA) for β 1 (ID:Rn00824536_s1) and for β 2 (ID:Rn005606650_s1), for α 1 (ID:Rn00567876_m1), and for α 2 (ID:Rn00562488_s1). A reference endogenous control was included in each analysis to correct the differences in the inter-assay amplifi cation effi ciency and all the transcripts were normalized to cyclophyline A (ID:Rn00690933) expression. Hippocampal tissue wase homogenized in RIPA Lysis Buffer System (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, sc-24948). After centrifugation (12 000rpm, 20 min at 4 °C), the supernatant was taken and protein concentration was determined by the method of Lowry et al (16) . For measuring α 1 , α 2 , β 1 and β 2 protein levels, a polyclonal anti-α 1 primary antibody, rabbit (sc28982, dilution 1:500, Santa Cruz Biotecnology, California, USA), a polyclonal anti-α 2 primary antibody, rabbit (sc28983, dilution 1:500, Santa Cruz Biotechnology, California, USA), polyclonal anti-β 1 primary antibody, rabbit (ab3442, dilution 1:1000, Abcam, Cambridge, UK) and polyclonal anti-β 2 primary antibody, rabbit (ab182136, dilution 1:1000 Abcam, Cambridge, UK) were used respectively. Rabbit polyclonal anti-β-actin (dilution 1:1000; Abcam, Cambridge, UK) was used to detect β-actin as a loading control. Washed membrane was further incubated in the horseradish peroxidase conjugated secondary anti-rabbit antibody for luminol based detection (ab6721, dilution 1:5000, Abcam, Cambridge, UK). Secondary antibody was then visualized by Immobil- ion Western Chemiluminescent HPR Substrate (Merck Millipore, Massachusetts, USA). Western blot analysis was performed as previously described by Gavrilovic et al (15) .
Statistical analysis
The results are reported as the mean ± S.E.M. Signifi cance of the differences in gene expression levels of the examined α 1 , α 2 , β 1 , and β 2 -adrenergic receptors in hippocampus of rats subjected to CUMS and melatonin treatment were estimated by Two-Way ANOVA test. The Tuckey post hoc test was used to evaluate the differences between the groups. Statistical signifi cance was accepted at p < 0.05. Results processing was done in the OriginPro, version 8.0 software program (OriginLab Corporation, Massachusetts, USA).
Results
The α 1 -adrenoceptor (F (1,23) = 16.04, p < 0.001) and α 2 -adrenoceptor (F (1,23) = 14.64, p < 0.01) mRNA levels were signifi cantly infl uenced by stress. Compared to the control group, a decrease was observed in α 1 -adrenoceptor (by 50 %, p < 0.001) and α 2 -adrenoceptor (by 69 %, p < 0.05) mRNA levels in the rats exposed to CUMS. Melatonin increased gene expression of α 1 -adrenoceptor in CUMS group (60 %, p < 0.05) (Fig. 1a) . Exposure of the rats to CUMS decreased protein levels of α 1 -adrenoceptor (by 80 %, p < 0.05) and α 2 -adrenoceptor (by 69 %, p < 0.05). Melatonin treatment induced an increase of α 1 -adrenoceptor protein levels (by 43 %, p < 0.05) in the hippocampus of stressed rats, without affecting α 2 -adrenoceptor protein content (Fig. 1b) .
No significant differences in the levels of mRNA β 1 -adrenoceptors and protein levels between the placebo and stressed groups were found. Chronic treatment with melatonin did not change β 1 -adrenoceptors gene expression and protein levels (Fig. 2a) .
Two-way ANOVA demonstrated a signifi cant effect of both CUMS (F (1,23) = 15.55, p < 0.001) and the melatonin treatment (F (1, 23) = 7.93, p < 0.05) on β 2 -adrenoceptors mRNA. Stress decreased mRNA (by 49 %, p < 0.01) levels of this adrenergic receptor. On the other hand, melatonin treatment increased β 2 -adrenoceptor mRNA (by 74 %, p < 0.01) in the stressed rats. Two-way ANO-VA also showed a signifi cant interaction between treatment and stress (F (1,23) = 8.78, p < 0.01) on β 2 -adrenoceptors protein levels. Post hoc testing showed that while stress produced a signifi cant reduction in protein content of this adrenergic receptor (by 33 %, p < 0.05), melatonin treatment prevented that CUMS-induced decrease (Fig. 2b) .
Discussion
Since α-and β-adrenoceptors are involved in the regulation of a variety of mental and bodily functions, it can be assumed that stress-induced changes in the central adrenoceptors system constitute a molecular basis for physiological changes in stressed individuals. α 1 -and α 2 -adrenoceptors are supposed to be important regulatory elements in responses to stress. Previous studies in male tree shrews showed that chronic psychosocial stress down-regulated biding sites for α 2 -adrenergic ligands in several brain stem nuclei such as: reduced α 2A -adrenoceptor mRNA expression in locus coeruleus, solitary tract neurons and neurons of lateral reticular nucleus (17) . Similarly, repeated stress signifi cantly decreased mRNA levels for α 1 -adrenoceptors in midbrain and hypothalamus (18) . Our results are consistent with previous work demonstrating a decreased gene expression of α 1 -and α 2 -adrenoceptors in the hippocampus of rats subjected to unpredictable chronic mild stress.
The mammalian hippocampus receives noradrenergic innervation and hippocampal neurons express β 1 -and β 2 -adrenoceptors. Both type of receptors are localized to the cell membrane and cytoplasm, however only β 2 -adrenoceptors are found in the nucleus (19) . The data presented here showed that CUMS caused a decrease of β 2 -adrenoceptors mRNA and protein levels, while there was no change in gene expression of β 1 -in the hippocampus. Our results are consistent with Flügge et al (20) , who reported that repeated exposure to subordination stress down-regulated β-adrenoceptors expression in the hippocampus. α 1 -and α 2 -adrenoreceptors and their signaling system were important targets of antidepressant drugs (21) . Kreiner et al (22) reported that in contrast to imipramine and electroconvulsive shock, which produce up-regulation of the α 1A -adrenoceptors mRNA expression, chronically administered citalopram did not affect the α 1A -adrenoceptors mRNA level in the prefrontal cortex. Our observations indicated that melatonin treatment in the CUMS rats prevented the stress-induced decrease in α 1 -mRNA and protein levels. On the other hand, melatonin treatment did not affect either mRNA or protein level of α 2 -adrenoceptors in the hippocampus of rats exposed to CUMS. Given that Stone and co-workers (23) reported that brain α 1 -adrenoceptors were impaired or inhibited in depressed patients or after stress in animal models, and were restored by a number of antidepressants, it is possible that melatonin mediated antidepressant-like effect by modulating the gene expression of α 1 -adrenoceptors in the hippocampus of CUMS rats.
Although α-adrenoceptors can infl uence hippocampal function, largely through regulating neuronal excitability, β -adrenoceptors exert very specifi c effects on synaptic information enconding (24) . Our data revealed that melatonin treatment prevented stress-induced decrease in the expression of β 2 -adrenoceptors in hippocampus of CUMS rats. β-adrenoceptors in hippocampus play an important role in regulating synaptic plasticity and memory consolidation. The activation of these adrenoceptors results in the stimulation of extracellular signal-regulated kinase/mitogenactivated protein kinase (ERK/MAPK) that is a key step in the activation of the cAMP response element-binding protein (CREB) that mediates protein transcription and thus strongly supports persistent synaptic plasticity and long-term memory (25) . Maity et al (26) reported that norepinephrine activating β-adrenoceptors could boost long-term potentiation, a putative cellular mechanism for memory formation. The hippocampus-dependent memory is impaired following a reduction of norepinephrine or after blockade of β-adrenoceptors (27) . Taken together, it gives rise to the possibility that melatonin-induced up-regulation of gene expression of β 2 -adrenoceptors in the hippocampus of CUMS rats could enhance long-term potentiation and learning and memory. Our fi ndings here provide novel targets for exploring the molecular mechanisms by which melatonin is improving mental health modulating through dysfunctional noradrenergic synaptic transmission. Recently, we reported that reduced noradrenaline content was increased in the hippocampus of stressed rats treated with melatonin (28) . The present results suggested that repeated treatment with melatonin might improve a reduced expression of α 1 -and β 2 -adrenoreceptors, and it was in a good correlation with increased noradrenaline in the hippocampus. Although the molecular basis of the gene regulation of α-and β-adrenoceptors in the hippocampus of rats exposed to CUMS during melatonin treatment remains to be elucidated, increased gene expression of α 1 -and β 2 -adrenoceptors provides an experimental opportunity to probe into further molecular mechanisms underlying the regulation of these receptor subtype. Further ex periments on transcriptional activation and mRNA stabil ity will be required to unravel the complexity of stress-and melatonindependent regulation of α-and β-adrenoceptor gene expression.
